• Lee Jae-Ha

• Song Jin-Woo

• 企尖己企龙券   2019  Volume.7  No.2 105 ~ 110

• Adverse Effect of Current Treatments in Airway Disease

• Park Heung-Woo

• 企尖己企龙券   2019  Volume.7  No.2 99 ~ 104

• Treatment of Severe Asthma: Anti-IgE or Anti-Eosinophils?

• Song Woo-Jung

• 企尖己企龙券   2019  Volume.7  No.2 94 ~ 98

• Airway Disease in Elderly; Can We Differentiate Asthma and COPD?

• Jung Ji-Ye

• 企尖己企龙券   2019  Volume.7  No.2 89 ~ 93

• Physical Activity in Patients with COPD

• Kim Ki-Uk

• 企尖己企龙券   2019  Volume.7  No.2 84 ~ 88

• Lee Sei-Won

• 企尖己企龙券   2019  Volume.7  No.2 80 ~ 83

• Role of Microbiome and Nanovesicles in Asthma and COPD

• Yang Jin-Ho

• Kim Yoon-Keun

• 企尖己企龙券   2019  Volume.7  No.2 75 ~ 79

• Optimal Management of Mild Asthma

• Lee Tae-Hoon

• 企尖己企龙券   2019  Volume.7  No.2 65 ~ 74

• Impacts of New Inhaler Devices on Clinical Outcomes in Patients with Asthma and Chronic Obstructive ...

• Cho Yu-Ji

• 企尖己企龙券   2019  Volume.7  No.2 60 ~ 64

• Innovation in Inhaler Devices

• Ra Seung-Won

• 企尖己企龙券   2019  Volume.7  No.2 53 ~ 59

• Kim Woo-Jin

• 企尖己企龙券   2019  Volume.7  No.2 49 ~ 52

• Jhun Byung-Woo

• 企尖己企龙券   2019  Volume.7  No.1 41 ~ 48

• IX Asthma-Chronic Obstructive Pulmonary Disease Overlap: Still in the Fog

• Lee Hyun, Park Hye-Yun

• 企尖己企龙券   2019  Volume.7  No.1 36 ~ 40

• VIII Asthma-COPD Overlap (ACO) Should Be Considered as a Distinct Phenotype?

• Jo Yong-Suk

• 企尖己企龙券   2019  Volume.7  No.1 32 ~ 35

• Innate Immunity in Asthma

• Kim Byung-Keun

• 企尖己企龙券   2019  Volume.7  No.1 28 ~ 31

• VI Debate on the Positioning of ICS as the First Combination Option in Group D of COPD: Con

• Rhee Chin-Kook

• 企尖己企龙券   2019  Volume.7  No.1 25 ~ 27

• Debate on the Positioning of ICS as the First Combination Option in Group D of COPD: Pro

• Lee Chang-Hoon

• 企尖己企龙券   2019  Volume.7  No.1 21 ~ 24

• Chun Eun-Mi

• 企尖己企龙券   2019  Volume.7  No.1 15 ~ 20

• Song Woo-Jung

• 企尖己企龙券   2019  Volume.7  No.1 10 ~ 14

• COPD-OSA Overlap Syndrome

• Cho Jae-Young

• 企尖己企龙券   2019  Volume.7  No.1 7 ~ 9